Get to know our clinical trials

Trial of cabozantinib in subjects with progressing renal cell carcinoma after first-line treatment with immune checkpoint inhibitors

THIS STUDY AIMS TO EXAMINE THE EFFECTS OF CABOZANTINIB IN SUBJECTS WITH RCC WITH A CLEAR CELL CARCINOMA COMPONENT (A SPECIAL TYPE OF KIDNEY CANCER), LOCALLY ADVANCED OR METASTATIC, INOPERABLE, THAT HAS PROGRESSED AFTER TREATMENT WITH IPC, WITH OR WITHOUT ANTI-VEGF.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • MULTICENTER, OPEN-LABEL, PHASE II STUDY OF CABOZANTINIB AS SECOND-LINE TREATMENT IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC, UNRESECTABLE, CLEAR CELL COMPONENT RENAL CELL CARCINOMA PROGRESSING AFTER FIRST-LINE IMMUNE CHECKPOINT INHIBITOR THERAPY
  • Code EudraCT: 2018-002820-18
  • Protocol number: F-FR-60000-023
  • Promoter: IPSEN
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.